D18

• Description :

  D18 is an immune modulator. D18 acts as a TLR7/8 dual agonist (EC50 = 24 nM for hTLR7 and 10 nM for hTLR8, respectively) . D18 increases PD-L1 expression through epigenetic regulation, thus sensitizing tumors to PD-1/PD-L1 blockade. D18 is a ADC cytotoxin uesd for the systhesis of ADC HE-S2 (HY-144497) . D18 has strong immune activation and anti-tumor activity. D18 commonly used in cancer research, such as colon cancer[1][2].

• UNSPSC :

  12352005

• Target :

  PD-1/PD-L1; Toll-like Receptor (TLR)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/d18.html

• Purity :

  98.79

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  NC(N=C1NCCCC)=NC(C1=N2)=CC=C2CC(C=C3)=CC=C3CN(C)C

• Molecular Formula :

  C21H28N6

• Molecular Weight :

  364.49

• References & Citations :

  [1]He L, et al. Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021;64 (21) :15716-15726. |[2]Wang Z, et al. Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy. J Med Chem. 2021 Jun 10;64 (11) :7507-7532.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2230218-36-5]